EMYRIA LIMITED — Proxy Solicitation & Information Statement 2021

Feb 2, 2021

==> picture [596 x 148] intentionally omitted <==

2 February 2021

Dear Shareholder

General Meeting – Notice and Proxy Form

Notice is hereby given that a General Meeting ( Meeting ) of Shareholders of Emyria Limited (ACN 625 085 734) (Company) will be held at the offices of BDO, 38 Station Street Subiaco Western Australia 6008 on 5 March 2021 at 10.00am (WST).

The Board has made the decision that it will hold a physical Meeting with the appropriate social gathering and physical distancing measures in place to comply with the Federal Government’s and State Government’s current restrictions for physical gatherings.

In accordance with subsection 5(f) of the Corporations (Coronavirus Economic Response) Determination (No. 1) 2020, the Company will not be dispatching physical copies of the Notice of Meeting ( NoM ). - Instead, a copy of the NoM is available under ASX ANNOUNCEMENTS at https://emyria.com/for investors/#ASX-Announcements

As you have not elected to receive notices by email, a copy of your personalised proxy form is enclosed for your convenience. Please complete and return the attached proxy form to the Company’s share registry, Automic Group Pty Ltd by:

post to: Automic GPO Box 5193 Sydney NSW 2001 or email to: meetings@automicgroup.com.au

Proxy votes may also be lodged online using the following link https://investor.automic.com.au/#/loginsah.

Your proxy voting instruction must be received by 10.00 am (AWST) on 3 March 2021, being not less than 48 hours before the commencement of the Meeting. Any proxy voting instructions received after that time will not be valid for the Meeting.

Circumstances relating to COVID-19 are changing rapidly. The Company will update shareholders if changing circumstances will impact planning or the arrangements for the Meeting by way of

==> picture [595 x 65] intentionally omitted <==

==> picture [596 x 72] intentionally omitted <==

announcement on ASX and the details will also be made available on our website at https://www.emyria.com.

The NoM is important and should be read in its entirety. If you are in doubt as to the course of action you should follow, you should consult your financial adviser, lawyer, accountant or other professional adviser. If you have any difficulties obtaining a copy of the Notice of Meeting please contact the Company’s share registry, Automic Group Pty Ltd on, 1300 288 664 (within Australia) or +61 2 9698 5414 (overseas).

Yours sincerely

==> picture [103 x 33] intentionally omitted <==

Simon Robertson Company Secretary

About Emyria (www.emyria.com)

Emyria Limited creates drug development programs for patients with unmet needs. These programs can be progressed by partners or independently. Emyria is uniquely placed to accomplish this by managing an independent specialist clinical network – Emerald Clinics (www.emeraldclinics.com.au) and by building bespoke remote patient monitoring technologies and clinical-trial-grade data platforms. Emyria uses these resources to turn its proprietary clinical data into Real World Evidence (RWE) and unique IP. Emyria’s RWE is the backbone of its patient care and drug development programs and provides insights into the safety, quality and efficacy of unapproved treatments, in real patients, in the community. Emyria RWE can greatly accelerate the registration of new treatments. Registered treatments can become available to a much wider population of patients via routine prescription pathways creating great value. Recently, Emyria announced the launch of its own drug development program to register new treatments for the growing challenge of mental health.